Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-07-31
2004-12-07
Weber, Jon P. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S015800, C530S327000, C530S328000, C530S329000
Reexamination Certificate
active
06828304
ABSTRACT:
FIELD OF INVENTION
This invention relates to novel antiproliferative and anti secrectory peptides that are inhibitory to vasoactive intestinal peptide receptor and are useful in the treatment of cancer. The invention particularly relates to the synthesis of lipid-peptide conjugates containing fatty acids of different sizes, which inhibits the binding of VIP to its receptors. The invention encompasses methods for generation of these peptides, composition containing these peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.
BACKGROUND OF THE INVENTION
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide, which was first isolated from the porcine intestine (Said, S. I. and Mutt, V., Science, 169, 1217-1218, 1970.) VIP acts as growth factor and plays dominant autocrine and paracrine role in the sustained proliferation of cancer cells. (Said, S. I., Peptides, 5, 143-150, 1984.) Gozes et al. have shown that VIP can serve as autocrine growth factor in lung tumors. (Gozes et al. Biomed. Res. 13 (suppl.2) 37, 1992).
The peptide sequence Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys (SEQ ID NO: 1) is reported to be receptor binding inhibitor of vasoactive intestinal peptide (Said, & Mutt, Ann. N.Y. Acad. Sci., 1, 527, 1988). The role this octapeptide as VIP receptor binding inhibitor has been described in the U.S. Pat. No. 5,217,953. In our U.S. patent application Ser. No. 08/727,679 we have described the anti cancer role of this VIP binding receptor inhibitor in combination with other neuropeptide analogs. In another U.S. patent application Ser. No. 09/248,382 we have described the novel analogs of this VIP receptor binding inhibitor incorporating dialkylated amino acids. Keeping in view that lipophilization of bioactive peptides improves their stability, bioavailability and the ability to permeate biomembranes (Dasgupta, P. et al.; 1999, Pharmaceutical Res. 16, 1047-1053; Gozes, I. et al., 1996, Proc. Natl. Acad. Sci. USA, 93, 427-432.), in the present invention we have synthesized lipid conjugates of the peptide sequence Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys (SEQ ID NO: 1) using fatty acids of different sizes, C2-C16 carbon atoms, at the N-terminal site of the peptide. Throughout the application the following abbreviation are used with the following meanings:
BOP: Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexofluorophospate
PyBOP: Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexofluorophospate
HBTU: O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexofluoro-phosphate
TBTU: 2-(1H-Benzotriazole-1yl)-1,1,3,3,-tetramethyluronium tetrafluoroborate
HOBt:
1-Hydroxy Benzotriazole
DCC:
Dicyclohexyl carbodiimide
DIPCD:
Diisopropyl carbodiimide
DIEA:
Diisopropyl ethylamine
DMAP:
4-Dimethylamino pyridine
DMF:
Dimethyl formamide
DCM:
Dichloromethane
NMP:
N-Methyl-2-pyrrolidinone
TFA:
Trifluoroacetic acid
Throughout the specification and claims, the amino acids residues are designated by their standard abbreviations. Amino acids denote L-configuration unless otherwise indicated by D or DL appearing before the symbol and separated from it by hyphen.
Throughout the specification and claims, the amino acids residues are designated by their standard abbreviations. Amino acids denote L-configuration unless otherwise indicated by D or DL appearing before the symbol and separated from it by hyphen.
SUMMARY OF THE INVENTION
The present invention relates to peptides of the following general formula
X-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-Y
wherein,
X is acetyl or straight, branched, or cyclic alkanoyl group of from 3-16 carbon atoms.
Y is a carboxy terminal residue selected from OH or amino; or a pharmaceutical acceptable salt of the peptides.
REFERENCES:
patent: 4605641 (1986-08-01), Bolin et al.
patent: 4734400 (1988-03-01), Bolin et al.
patent: 4835252 (1989-05-01), Musso et al.
patent: 4866039 (1989-09-01), Wootton et al.
patent: 5141924 (1992-08-01), Bolin
patent: 5217953 (1993-06-01), Fridkin et al.
patent: 5376637 (1994-12-01), Sawai et al.
patent: 5428015 (1995-06-01), Kurono et al.
patent: 5565424 (1996-10-01), Gozes et al.
patent: 5677419 (1997-10-01), Bolin et al.
patent: 5849261 (1998-12-01), Dean et al.
patent: 6007792 (1999-12-01), Dean et al.
patent: 6492330 (2002-12-01), Mukherjee et al.
patent: 0354992 (1990-02-01), None
patent: 0835662 (1998-04-01), None
patent: 0023096 (2000-04-01), None
H. Frucht et al.; Characterization of Functional Receptors for Gastrointestinal Hormones on Human Colon Cancer Cells; Cancer Research 52; 1114-1122; Mar. 1, 1992.
Irene Virgolini et al.; Vasoactive Intestinal Peptide-Receptor Imagine for the Localization of Intestinal . . . Tumors; New England Journal of Medicine; vol. 331 (17); 1116-1121; Oct. 27, 1994.
G.Lilling et al.; Inhibition of Human Neuroblastoma Growth by a Specific VIP Antagonist; Journal of Molecular Neuroscience; vol. 5, 1994/1995; 231-239.
Gozes et al.; Vasoactive Intestinal Peptide Potentiates Sexual Behavior; Inhibition by Novel Antagonist Endocrinology; vol. 125, No. 6; 2945-2949; (1989).
Burman Anand C.
Jaggi Manu
Mukherjee Rama
Prasad Sudhanand
Sharma Rajan
Dabur Research Foundation
Ladas & Parry
Mohamed Abdel A.
Weber Jon P.
LandOfFree
Peptides for treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides for treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3304246